{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:19:47Z","timestamp":1787750387124,"version":"build-2784847793"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>To systematically evaluate the spectrum, mechanisms, and prevention strategies of gastrointestinal (GI) adverse effects associated with subcutaneously administered drug therapies across multiple therapeutic classes. A comprehensive literature search was conducted in PubMed, EMBASE, and the Cochrane Library for studies published from January 2000 to June 2025. Eligible publications included randomized trials, observational studies, systematic reviews, meta-analyses, and regulatory label data reporting GI adverse effects of subcutaneous therapies. Drug classes analyzed included metabolic and endocrine agents, hematopoietic and bone-active drugs, cytokine modulators, biologic immunotherapies, vaccines, and selected miscellaneous agents. Data were extracted on incidence, clinical manifestations, mechanistic pathways, and mitigation strategies. Subcutaneously administered drugs were consistently associated with a wide range of GI adverse effects, including nausea, vomiting, diarrhea, abdominal pain, dyspepsia, and mucosal inflammation. Prominent contributors included glucagon-like peptide-1 receptor agonists, insulin analogs, growth factors, cytokine modulators, and biologic therapies. Mechanistic pathways identified included delayed gastric emptying, vagal and enteric nervous system activation, cytokine-mediated epithelial dysfunction, immune activation, and alterations of the gut microbiome. Interindividual variability in metabolic, immunologic, and neurohumoral responses influenced susceptibility. Despite bypassing the GI tract, subcutaneous therapies can induce clinically relevant GI toxicity through systemic neurohormonal, immune, and microbial pathways. Recognition of these mechanisms supports the use of dose titration, administration timing, dietary modification, and prophylactic pharmacotherapy to improve tolerability and treatment adherence.<\/jats:p>","DOI":"10.4103\/ijp.ijp_1343_25","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T18:00:11Z","timestamp":1782410411000},"page":"307-318","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Systemic pathways linking subcutaneous therapies to gastrointestinal adverse effects: A Narrative review of mechanisms and mitigation strategies"],"prefix":"10.4103","volume":"58","author":[{"given":"Alok","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudan Prasad","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"R2-20260626","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/flgastro-2013-100316","article-title":"Drug-induced gastrointestinal disorders","volume":"5","author":"Philpott","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"R3-20260626","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40259-020-00465-4","article-title":"Immunogenicity challenges associated with subcutaneous delivery of therapeutic proteins","volume":"35","author":"Jarvi","year":"2021","journal-title":"BioDrugs"},{"key":"R15-20260626","doi-asserted-by":"crossref","first-page":"1149328","DOI":"10.3389\/fendo.2023.1149328","article-title":"GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R17-20260626","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.2000.278.6.G946","article-title":"Pramlintide, an amylin analog, selectively delays gastric emptying: Potential role of vagal inhibition","volume":"278","author":"Samsom","year":"2000","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R19-20260626","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4292\/wjgpt.v11.i2.17","article-title":"Gastrointestinal symptoms in acromegaly: A case control study","volume":"11","author":"Inayet","year":"2020","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"R22-20260626","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s11095-016-1868-6","article-title":"Exploration of antiemetics for osteoporosis therapy-induced nausea and vomiting using PET molecular imaging analysis to gastrointestinal pharmacokinetics","volume":"33","author":"Shingaki","year":"2016","journal-title":"Pharm Res"},{"key":"R24-20260626","doi-asserted-by":"crossref","first-page":"13","DOI":"10.33393\/dti.2012.2403","article-title":"Expression of luteinizing hormone receptor in the gastrointestinal tract in patients with and without dysmotility","volume":"6","author":"Hammar","year":"2012","journal-title":"Drug Target Insights"},{"key":"R25-20260626","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/117739280700200009","article-title":"New insights into the understanding of gastrointestinal dysmotility","volume":"2","author":"Ohlsson","year":"2007","journal-title":"Drug Target Insights"},{"key":"R29-20260626","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7827-11-20","article-title":"Optimal usage of the GnRH antagonists: A review of the literature","volume":"11","author":"Copperman","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"R30-20260626","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10620-018-4939-1","article-title":"Effects of estrogen on the gastrointestinal tract","volume":"63","author":"Nie","year":"2018","journal-title":"Dig Dis Sci"},{"key":"R32-20260626","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fendo.2017.00110","article-title":"Gonadotropin-releasing hormone and its role in the enteric nervous system","volume":"8","author":"Ohlsson","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R34-20260626","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nut.2010.07.004","article-title":"Diverse roles of leptin in the gastrointestinal tract: Modulation of motility, absorption, growth, and inflammation","volume":"27","author":"Yarandi","year":"2011","journal-title":"Nutrition"},{"key":"R36-20260626","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.gtc.2011.03.009","article-title":"Nausea and vomiting of pregnancy","volume":"40","author":"Lee","year":"2011","journal-title":"Gastroenterol Clin North Am"},{"key":"R37-20260626","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.bpg.2007.05.008","article-title":"Review on hyperemesis gravidarum","volume":"21","author":"Ismail","year":"2007","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R39-20260626","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/0974-1208.86080","article-title":"Ovarian hyperstimulation syndrome","volume":"4","author":"Kumar","year":"2011","journal-title":"J Hum Reprod Sci"},{"key":"R46-20260626","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1182\/blood.V92.12.4491","article-title":"Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor","volume":"92","author":"Armitage","year":"1998","journal-title":"Blood"},{"issue":"(11)","key":"R48-20260626","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-014-0226-z","article-title":"Side effects of cytokines approved for therapy","volume":"37","author":"Baldo","year":"2014","journal-title":"Drug Saf"},{"key":"R50-20260626","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1136\/gutjnl-2011-300539","article-title":"IL-11 is a parietal cell cytokine that induces atrophic gastritis","volume":"61","author":"Howlett","year":"2012","journal-title":"Gut"},{"key":"R52-20260626","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s00535-008-2241-2","article-title":"Downregulation of CPI-17 contributes to dysfunctional motility in chronic intestinal inflammation model mice and ulcerative colitis patients","volume":"43","author":"Ohama","year":"2008","journal-title":"J Gastroenterol"},{"key":"R53-20260626","doi-asserted-by":"crossref","first-page":"48794","DOI":"10.1074\/jbc.M310166200","article-title":"Chronic treatment with interleukin-1beta attenuates contractions by decreasing the activities of CPI-17 and MYPT-1 in intestinal smooth muscle","volume":"278","author":"Ohama","year":"2003","journal-title":"J Biol Chem"},{"key":"R54-20260626","doi-asserted-by":"crossref","first-page":"G1429","DOI":"10.1152\/ajpgi.00315.2006","article-title":"Intestinal inflammation downregulates smooth muscle CPI-17 through induction of TNF-alpha and causes motility disorders","volume":"292","author":"Ohama","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R55-20260626","doi-asserted-by":"crossref","first-page":"C1991","DOI":"10.1152\/ajpcell.00300.2007","article-title":"Upregulation of RGS4 and downregulation of CPI-17 mediate inhibition of colonic muscle contraction by interleukin-1beta","volume":"293","author":"Hu","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"R56-20260626","doi-asserted-by":"crossref","first-page":"C1310","DOI":"10.1152\/ajpcell.00573.2008","article-title":"Upregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1\/2 and p38 MAPK and inhibited by the PI3K\/Akt\/GSK3beta pathway","volume":"296","author":"Hu","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"key":"R62-20260626","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0377-1237(17)30757-8","article-title":"Octreotide in gastroenterology","volume":"53","author":"Chaudhry","year":"1997","journal-title":"Med J Armed Forces India"},{"key":"R64-20260626","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2125.1997.tb00139.x","article-title":"Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans","volume":"43","author":"Lamrani","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R66-20260626","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/intimm\/dxu051","article-title":"Pleiotropic functions of TNF-\u03ba in the regulation of the intestinal epithelial response to inflammation","volume":"26","author":"Leppkes","year":"2014","journal-title":"Int Immunol"},{"key":"R69-20260626","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138945009788488440","article-title":"HER2 targeted therapies for cancer and the gastrointestinal tract","volume":"10","author":"Al-Dasooqi","year":"2009","journal-title":"Curr Drug Targets"},{"key":"R71-20260626","doi-asserted-by":"crossref","first-page":"20332","DOI":"10.1002\/cam4.6619","article-title":"Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma","volume":"12","author":"Bisht","year":"2023","journal-title":"Cancer Med"},{"key":"R73-20260626","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"R74-20260626","first-page":"121","article-title":"Molecular cardiotoxic effects of proteasome inhibitors carfilzomib and ixazomib and their combination with dexamethasone involve mitochondrial dysregulation","volume":"23","author":"Jannuzzi","year":"2023","journal-title":"Cardiovasc Toxicol"},{"key":"R75-20260626","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000500976","article-title":"The human microbiota in multiple myeloma and proteasome inhibitors","volume":"143","author":"Alkharabsheh","year":"2020","journal-title":"Acta Haematol"},{"key":"R77-20260626","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2741\/1241","article-title":"Signaling the brain in systemic inflammation: Role of sensory circumventricular organs","volume":"9","author":"Roth","year":"2004","journal-title":"Front Biosci"},{"key":"R82-20260626","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1043-6618(05)80101-X","article-title":"Regulation of serotonin release from the intestinal mucosa","volume":"23","author":"Rack\u00e9","year":"1991","journal-title":"Pharmacol Res"},{"key":"R83-20260626","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/BF03025695","article-title":"Central mechanisms of vomiting related to catecholamine response: Anaesthetic implication","volume":"18","author":"Jenkins","year":"1971","journal-title":"Can Anaesth Soc J"},{"key":"R84-20260626","doi-asserted-by":"crossref","first-page":"1098032","DOI":"10.3389\/fendo.2023.1098032","article-title":"Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes","volume":"14","author":"Wu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R85-20260626","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.2337\/dc18-1091","article-title":"Control of postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration of pramlintide and regular human insulin: A randomized, two-way crossover study","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"key":"R86-20260626","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40885-024-00279-4","article-title":"The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: A position paper from the Korean society of hypertension","volume":"30","author":"Lee","year":"2024","journal-title":"Clin Hypertens"},{"key":"R87-20260626","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"R88-20260626","first-page":"558","article-title":"The role of somatostatin in the gastrointestinal tract","volume":"14","author":"Papantoniou","year":"2025","journal-title":"Biology (Basel)"},{"key":"R89-20260626","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/imj.14241","article-title":"Is there a role for proton pump inhibitor prophylaxis in haematology patients?","volume":"49","author":"Leitinger","year":"2019","journal-title":"Intern Med J"},{"key":"R90-20260626","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.3390\/curroncol29050243","article-title":"The chemo-gut pilot study: Associations between gut microbiota, gastrointestinal symptoms, and psychosocial health outcomes in a cross-sectional sample of young adult cancer survivors","volume":"29","author":"Deleemans","year":"2022","journal-title":"Curr Oncol"},{"key":"R91-20260626","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01535722","article-title":"GSRS \u2013 A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease","volume":"33","author":"Svedlund","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R92-20260626","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2020.08.079","article-title":"Impact of the intestinal environment on the immune responses to vaccination","volume":"38","author":"Hosomi","year":"2020","journal-title":"Vaccine"},{"key":"R93-20260626","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J Pharm Sci"},{"key":"R94-20260626","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijcp.12847","article-title":"Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: A systemic review of randomised controlled trials","volume":"70","author":"Xue","year":"2016","journal-title":"Int J Clin Pract"},{"key":"R95-20260626","doi-asserted-by":"crossref","first-page":"7655","DOI":"10.2147\/OTT.S181335","article-title":"A systematic review and meta-analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors","volume":"11","author":"Wu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R96-20260626","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/bs.acr.2022.02.007","article-title":"Chemotherapy induced gastrointestinal toxicities","volume":"155","author":"Akbarali","year":"2022","journal-title":"Adv Cancer Res"},{"key":"R97-20260626","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3348\/kjr.2008.9.5.449","article-title":"Gastrointestinal complications following hematopoietic stem cell transplantation in children","volume":"9","author":"Lee","year":"2008","journal-title":"Korean J Radiol"},{"key":"R98-20260626","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.molonc.2012.03.001","article-title":"Hematopoietic growth factors: Personalization of risks and benefits","volume":"6","author":"Puhalla","year":"2012","journal-title":"Mol Oncol"},{"key":"R99-20260626","first-page":"391","article-title":"Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis","volume":"55","author":"Catrina","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R100-20260626","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3390\/pharmaceutics14112328","article-title":"Real-world safety profile of biologics used in rheumatology: A six-year observational pharmacovigilance study in the Calabria region","volume":"14","author":"Gagliardi","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1343_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:27:56Z","timestamp":1787747276000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_1343_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_1343_25","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-12-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}